DSIP Delta sleep-inducing peptide

DSIP

Delta sleep-inducing peptide 

Discovery

Delta sleep-inducing peptide was first discovered in 1974 by the Swiss Schoenenberger-Monnier group who isolated it from the cerebral venous blood of rabbits in an induced state of sleep. It was primarily believed to be involved in sleep regulation due to its apparent ability to induce slow-wave sleep . 

Delta-sleep-inducing peptide (DSIP)-like material has been found in human breast milk.^[3]
 (MCH). It is abundant in the gut secretory cells and in the pancreas where it co-localises with glucagon.^[4]
In the brain its action may be mediated by NMDA receptors.^[6] In another study Delta sleep-inducing peptide stimulated natural sleep.

• Decreases basal corticotropin level and blocks its release.^[8]
• Stimulates release of luteinizing hormone (LH).^[15]
• Stimulates release of somatoliberin and somatotrophin secretion and inhibits somatostatin secretion.^[16]

Roles in physiological processes

• Can act as a stress limiting factor.^[17][18][19]
• May have a direct or indirect effect on body temperature and alleviating hypothermia.^[20][21][22]
• Can normalize blood pressure and myocardial contraction.^[8][23]
• It has been shown to enhance the efficiency of oxidative phosphorylation in rat mitochondria in vitro, suggesting it may have antioxidant effects.^[19]
• There is also conflicting evidence as to its involvement in sleep patterns. Some studies suggest a link between DSIP and slow-wave sleep (SWS) promotion^[24][25] and suppression of paradoxical sleep, (PS)^[26][27] while some studies show no correlation.^[28] Stronger effects on sleep have been noted for the synthesized analogues of DSIP.^[29]
• It may have an impact on human lens epithelial cell function via the MAPK pathway, which is involved in cell proliferation, differentiation, motility, survival, and apoptosis.^[12]

Roles in Disease and Medicine

• It has been found to have anticarcinogenic properties. In a study on mice, injecting a preparation of DSIP over the mice's lifetime decreased total spontaneous tumor incidence 2.6-fold.^[30]

• The same study found it to also have geroprotective effects: it slowed down the age-related switching-off of oestrous function; it decreased by 22.6% the frequency of chromosome aberrations in bone marrow cells and it increased by 24.1% maximum life span in comparison with the control group.

• Levels of DSIP may be significant in patients diagnosed with major depressive disorder (MDD). In several studies, levels of DSIP in the plasma and cerebrospinal fluid are significantly deviated from the norm in patients with MDD.

• Studies have demonstrated a direct link between GILZ expression (homologous to DSIP) and adipogenesis which has links to obesity and metabolic syndrome.^[33]

• In studies on rats with metaphit-induced epilepsy DSIP acted as an anticonvulsant, significantly decreasing the incidence and duration of fits suggesting DSIP as a potential treatment for epilepsy.^[34][35]

• DSIP has been found to have an analgesic effect.).^[36]

• Due to its possible effects on sleep and nociception, trials have been carried out to determine whether DSIP can be used as an anaesthetic. One such study found that administration of DSIP to humans as an adjunct to isoflurane anaesthesia actually increased the heart rate and reduced the depth of anaesthesia instead of deepening it as expected.^[37]

• Low plasma concentrations of DSIP have been found in patients with Cushing's syndrome.^[38]

• DSIP can act antagonistically on opiate receptors to significantly inhibit the development of opioid and alcohol dependence and is currently being used in clinical trials to treat withdrawal syndrome .^[41][42]  
• In one such trial it was reported that in 97% of opiate-dependent and 87% of alcohol-dependent patients the symptoms were alleviated by DSIP administration.^[43]

• In some studies administration of DSIP has alleviated narcolepsy and normalized disturbed sleeping patterns.^[44][45]

Safety and possible side-effects of DSIP use has been established in clinical research studies.

References

1.                               

·  Monnier M, Dudler L, Gächter R, Maier PF, Tobler HJ, Schoenenberger GA (April 1977). "The delta sleep inducing peptide (DSIP). Comparative properties of the original and synthetic nonapeptide". Experientia 33 (4): 548–52. doi:10.1007/BF01922266. PMID 862769.
·  ·  Schoenenberger GA, Maier PF, Tobler HJ and Monnier M (1977). "A naturally occurring delta-EEG enhancing nonapeptide in rabbits". European Journal of Physiology 369 (2): 99–109. doi:10.1007/BF00591565. PMID 560681.
·  ·  Graf MV, Hunter CA, Kastin AJ (1984). "Presence of Delta-Sleep-Inducing Peptide-Like Material in Human Milk". Journal of Clinical Endocrinology & Metabolism 59 (1): 127–32. doi:10.1210/jcem-59-1-127. PMID 6547144.
·  Kovalzon VM and Strekalova TV (2006). "Delta sleep-inducing peptide (DSIP): a still unresolved riddle". Journal of Neurochemistry 97 (2): 303–309. doi:10.1111/j.1471-4159.2006.03693.x. PMID 165
European Journal of Anaesthesiology:
July 2001 - Volume 18 - Issue 7 - pp 419-422
Editorial

Can a  few tablespoons of real kefir and a few drops of DSIP change your world?

TDNorth

Delta sleep-inducing peptide

Pollard, B. J.¹; Pomfrett, C. J. D.²

Free Access
Article Outline

Author Information

¹Professor of Anaesthesia, University Department of Anaesthesia, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
²Lecturer in the Neurophysiology of Anaesthesia, University Department of Anaesthesia, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK


Delta sleep-inducing peptide


Delta sleep-inducing peptide (DSIP) is a naturally occurring substance, which was originally isolated from rabbit brain in 1977 [¹]. This curious substance is a nonapeptide that is normally synthesized in the hypothalamus and targets multiple sites including some within the brainstem [²]. As its name suggests DSIP promotes sleep and this has been demonstrated in human beings [^3–5]. In fact DSIP promotes a particular type of sleep which is characterized by an increase in the delta rhythm of the EEG.


DSIP is normally present in minute amounts in the blood.
Brain and plasma DSIP concentrations exhibit a marked diurnal variation [⁶] and there has been shown to be a correlation between DSIP plasma concentrations and circadian rhythm in human beings. Concentrations are low in the mornings and higher in the afternoons. 

An elevation of endogenous DSIP concentration has been shown to be associated with suppression of both slow-wave sleep and rapid-eye-movement sleep and interestingly also with body temperature [⁷]. Plasma concentrations of DSIP are influenced by the initiation of sleep [⁸].

Patients with Cushing’s syndrome suffer from a lack of slow-wave sleep but the diurnal variation in slow-wave and rapid-eye-movement sleep in those patients appears to be similar to that in normal patients [⁹].

When compared with most other peptides, DSIP is unusual in that it can freely cross the blood–brain barrier and is readily absorbed from the gut without being denatured by enzymes [^10,11]. 

DSIP is present in relatively high concentrations in human milk (10–30 ng mL^–1). Any mother who has breast-fed her babies will attest to the ability of a feed to induce sleep. However, a feed of artificial milk may have a similar effect, and it is not known whether DSIP concentrations are related to the sleep–wake cycle in human neonates [¹²].

DSIP has been synthesized. ISO standards

Administration of the synthetic substance does not induce tolerance [¹³]. 

DSIP can be assayed by several techniques including radioimmunoassay (RIA), enzyme immunoassay and high-performance liquid chromatography with RIA [^14–16]. DSIP has a half-life in human plasma of between 7 and 8 min [²]. It is degraded in blood, the pathway involving the amino-peptidases [¹⁷].

A potential drug interaction might therefore be envisaged between DSIP and drugs which inhibit or are themselves metabolized by peptidases. Captopril is one such agent and patients currently undergoing treatment with any of the angiotensin-converting enzyme inhibitors should probably be excluded from any DSIP treatment protocol until further studies have been undertaken.
Back to Top | Article Outline

DSIP and sleep

The innate controlling mechanisms of sleep have fascinated scientists for generations and many different endogenous compounds have been proposed as controllers of sleep over the years. 
These include cholecystokinin, prostaglandin I2 and various unknown substances labelled ‘sleep-promoting substances’. Indeed, the majority of humoral mediators seem to have some relation to sleep by, for example, affecting circadian rhythms or arousal states. In some cases, however, it is not clear if the humoral mediator is driving the sleep pattern or responding to the sleep pattern.

Since the discovery of DSIP a number of studies have been undertaken to test the hypothesis that DSIP may be the principal endogenous sleep factor. 

It is reported to increase the ‘pressure to sleep’ in human subjects who have been injected with small doses and this, together with its ability to induce delta-wave sleep, led to its consideration as a treatment for insomnia. A number of studies have examined this use with varied success [^18–21].

DSIP has been described as a sleep-promoting substance rather than a sedative. There is a modulating effect on sleep and wake functions with a greater activity in circumstances where sleep is disturbed.

 There are minimal effects in healthy subjects who are not suffering from sleep disturbance [²²]. 

DSIP is not a night sedation drug which needs to be given just before retiring. A dose of DSIP given during the course of the day will promote improved sleep on the next night and for several nights thereafter. Despite these clear short-term benefits, however, doubt has been cast on whether or not DSIP treatment will prove to be of major benefit in long-term management of insomnia.

Studies have been undertaken in patients suffering from the sleep apnoea syndrome and from narcolepsy. Unfortunately, no difference in DSIP concentrations has been found between those patients and normal patients [²³]. 

 DSIP may, paradoxically, be of use in the treatment of narcolepsy and it is possible that it exerts its effect by restoring circadian rhythms [²⁴]. 

 When single and multiple injections of DSIP were given in a controlled double-blind study, disturbed sleep was normalized and better performance and increased alertness was seen during awake cycles together with improved stress tolerance and coping behaviour [²²].
Back to Top | Article Outline

Non-sleep effects

DSIP has been shown to have an anticonvulsant action in the rat.

The threshold to NMDA- and picrotoxin-induced convulsions is increased by DSIP [^25,26]. This anticonvulsant effect may undergo a diurnal variation with greater antiepileptic activity seen at night [²⁷]. 

DSIP is not unique in possessing a diurnal variation in anticonvulsant activity as melatonin, b-endorphin and dexamphetamine all reduce seizure threshold during the day and it is possible that DSIP simply represents one of the endogenous controls of brain excitability [²⁸]. DSIP has an antinociceptive action in mice, an effect which is blocked by naloxone [²⁹].

A neuroprotective effect has been demonstrated in rats subjected to bilateral carotid ligation [³⁰]. 


A reduced mortality was observed together with a reduction in postischaemia function. DSIP also reduced brain swelling in a model of toxic cerebral oedema in the rat [³¹].

DSIP attenuates emotional and psychological responses to stress and also reduces the central amine responses to stress in rats [³²]. The action of corticotrophin releasing factor on the pituitary gland in the rat is attenuated with a consequential inhibition of pituitary adrenocorticotrophic hormone (ACTH) secretion [³³]. The situation is less clear in man as although one study confirmed this finding [³⁴] another reported no inhibitory effect on the adrenocortical axis to both physiological and stressor stimuli [³⁵]. DSIP had no effect on growth hormone or prolactin concentrations when administered to human volunteers [³⁶]. In one study, infusions of 3 or 4 mg (an enormous dose) had no effect on ACTH levels or on cortisol secretion [³⁵] although in another study DSIP 25 nmol kg^–1 significantly decreased ACTH concentrations [³⁶].


DSIP concentrations change during certain psychiatric disorders. Patients suffering from schizophrenia and depression have lower plasma and cerebrospinal fluid concentrations of DSIP than comparable normal volunteers [³⁷]. Concentrations were also inversely correlated with sleep disturbance in those patients.

As might be expected of any substance which is naturally occurring, side-effects are uncommon. 
Normally, concentrations would be very low and therefore the injection of large, probably non-physiological doses might be expected to at least produce some unwanted effect.

 No significant side-effects have so far been reported with DSIP. 

 In some human studies, transient headache, nausea and vertigo have been reported. DSIP actually appears to be incredibly safe as its LD₅₀ has never been determined because it has never so far proved possible to kill an animal whatever the dose of DSIP administered.
Back to Top | Article Outline

Clinical uses

Clinical uses for DSIP already exist. 

The agent has been used for the treatment of alcohol and opioid withdrawal with some success [³⁸]. 
Clinical symptoms and signs disappear after injection of DSIP although some patients have reported occasional headaches.

DSIP possesses a number of other apparently unrelated properties. 

In hypertensive rats, 200 μg kg⁻¹ day⁻¹of DSIP for 10 days had an antihypertensive effect [³⁹]. 
DSIP has also been reported to possess antimetastatic activity [⁴⁰]. 

It may also reduce amphetamine-induced hyperthermia and may be beneficial in some chronic pain conditions [⁴¹].

An interesting study reported in 1986 injected DSIP and several analogues of the peptide directly into the cerebral ventricle of rats. DSIP did not increase sleep and this was thought to be due to its very rapid metabolism. 

However, two of the analogues did induce sleep but one produced arousal. It would appear therefore that there might be the potential for not only sleep but sleep reversal within the analogues of DSIP [⁴²].A word of caution here, lab rats don't experience sleep wake

The molecular sites for the action of anaesthetic agents are being identified. Volatile agents appear to act on specific sites of the GABA-A and glycine receptors, whereas ketamine and xenon act on the NMDA receptors. These sites are reproducible and clearly defined, but what is their natural purpose, as neither volatile anaesthetic agents nor xenon are usually found in physiological systems? It is possible, but has yet to be demonstrated, that DSIP and other neuroactive peptides selectively bind to these regions of GABA-A, glycine and/or NMDA receptors.
Back to Top | Article Outline